One-Pot, Three-Component Approach to the Synthesis of 3,4,5-Trisubstituted Pyrazoles

Ahmed Kamal,^{*,†,‡} K. N. Visweswara Sastry,^{†,‡} D. Chandrasekhar,[†] Geeta Sai Mani,^{†,‡} Praveen Reddy Adiyala,[†] Jagadeesh Babu Nanubolu,[§] Kiran Kumar Singarapu,^{||} and Ram Awatar Maurya^{*,†}

[†]Division of Medicinal Chemistry and Pharmacology, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India [‡]Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, Hyderabad 500037, India [§]Centre for X-ray Crystallography, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India ^{II}Centre for Nuclear Magnetic Resonance, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India

Supporting Information

ABSTRACT: An operationally simple and high yielding protocol for the synthesis of polyfunctional pyrazoles has been developed through one-pot, three-component coupling of aldehydes, 1,3-dicarbonyls, and diazo compounds as well as tosyl hydrazones. The reaction proceeds through a tandem Knoevenagel condensation, 1,3-dipolar cycloaddition, and



transition metal-free oxidative aromatization reaction sequence utilizing molecular oxygen as a green oxidant. The scope of the reaction was studied by varying the aldehyde, 1,3-dicarbonyl, and diazo component individually.

INTRODUCTION

Pyrazole is among the most important privileged scaffolds found in synthetic and natural products¹ of medicinal interest. Pyrazole containing molecules possess a wide range of biological activities such as antibacterial,² antiviral,³ anticancer,⁴ antidiabetic,⁵ antiobesity,⁶ anti-inflammatory,⁷ estrogen receptor agonistic,⁸ cannabinoid receptor antagonistic,⁹ etc. Apart from their medicinal values, polysubstituted pyrazoles have been utilized for many other purposes, such as ligands for cross coupling reactions¹⁰ and dyes.¹¹ Considering the valuable potential of pyrazoles, numerous synthetic methods have been developed over the past decades.

There are two classical methods for the synthesis of pyrazoles, (1) 1,3-dipolar cycloaddition reaction of diazo compounds with alkynes and (2) condensation reaction of 1,3-dicarbonyls with hydrazines.¹² Although these methods provide pyrazoles in acceptable yields, they suffer from their own limitations such as the use of hazardous transition metals and carcinogenic hydrazines, limited substrate scope, and poor regioselectivity. Therefore, pyrazole synthesis was investigated extensively, and several improved synthetic routes were developed.¹³⁻¹⁸ Most of these methods rely on the reaction of diazo compounds (isolated or generated in situ from corresponding tosyl hydrazones) with alkenes having an appropriate leaving group (Figure 1, eqs 1-3). Zhang et al. developed a synthetic route for pyrazoles through 1,3-dipolar cycloaddition reaction of in situ generated diazo compounds with vinyl azides.¹⁴ The reaction of diazo compounds with β nitrostyrenes has been reported for the synthesis of pyrazoles. Furthermore, β -nitrostyrenes have been reacted with diazo compounds containing phosphonate and sulfonyl groups to



Figure 1. Various approaches for the synthesis of pyrazoles based on the reaction of alkenes with diazo compounds.

provide pyrazoles with corresponding functionality.¹⁶ Moreover pyrazoles have been synthesized via the reaction of enol triflates¹⁷ or enaminones (generated in situ from carbonyls and amines)¹⁸ with diazo compounds.

Many of the above-mentioned pyrazole synthetic routes require special substrates or reagents (vinyl azides, nitroalkenes, enol triflates, etc.) for the success of the reaction, which

Received: December 30, 2014 Published: April 7, 2015

ACS Publications © 2015 American Chemical Society

eventually limit the product diversity too. Therefore, a straightforward, operationally simple, and high yielding protocol for polysubstituted pyrazoles from easily available starting materials is highly needed. Presented in this paper are the results of one-pot, three-component coupling of aldehydes, 1,3-dicarbonyls, and diazo compounds or tosyl hydrazones to yield 3,4,5-trisubstituted pyrazoles.

RESULTS AND DISCUSSION

In order to study the feasibility of the cleavage of the acetyl group and aerobic aromatization, we started investigating a 1,3-dipolar cycloaddition reaction of 3-(4-chlorobenzylidene)-pentane-2,4-dione, **1aa**, with ethyl diazoacetate (EDA) **2a** (Table 1). First the reaction was attempted under open

Table 1. Optimization of Pyrazole Formation from 3-(4-Chlorobenzylidene)pentane-2,4-dione, 1aa, with EDA^a



^{*a*}Reaction conditions: **1aa** (1 mmol), **2a** (1.01 mmol), solvent (1 mL), stir in open atmosphere. ^{*b*}Isolated yield. ^{*c*}Reaction was carried out under oxygen atmosphere. ^{*d*}Not determined.

atmospheric conditions in toluene. The reaction was very slow at room temperature, and the substrate remained unreacted even after a week (Table 1, entry 1). The reaction was accelerated at elevated temperature, and heating it at 70 °C for a period of 24 h lead to the complete consumption of the starting materials (Table 1, entry 2). The reaction performed under oxygen atmospheric conditions did not significantly improve the yield of **3aaa** 68% (Table 1, entry 3). Among the several solvents screened, DMSO was found to be the best in the terms of reaction time and yield (Table 1, entry 7). Since no base was needed for the formation of **3aaa**, one of the acetyl groups was presumably cleaved by the traces of water present in the reaction medium. Analyzing ¹H NMR spectrum of the crude reaction mixture revealed that acetic acid was a byproduct of the reaction.

After confirming the feasibility of acetyl cleavage and aerobic oxidative aromatization, we sought to develop a one-pot, threecomponent version of the pyrazole synthesis. Therefore, an equimolar mixture of 4-Cl-benzaldehyde (4a), acetyl acetone (5a), and EDA (ratio 1/1/1.01) containing 20 mol % of piperidinium acetate was heated at 70 °C in DMSO under open atmosphere for a period of 12 h. After workup and purification of the crude reaction mixture, pyrazole **3aaa** was obtained in 55% yield. Since the yield of pyrazole **3aaa** was not satisfactory, we attempted to carry out the reaction in a one-pot, two-step fashion. Hence an equimolar mixture of 4-Cl-benzaldehyde and acetyl acetone (1 mmol each) was treated with 20 mol % of piperidinium acetate under solvent-free conditions and stirred well. Formation of **1aa** was complete in about 10 min (TLC). Then 1 mL of DMSO and 1.01 mmol of EDA were added to the reaction mixture, and the mixture was heated at 70 °C for 12 h under open atmosphere. We were pleased to achieve a high yield of pyrazole **3aaa** (80%) using the one-pot, two-step strategy. Though the one-pot, multicomponent approach gave a slightly lower yield of the pyrazole **3aaa** (80%) compared with the direct approach (84%), the added advantages of the multicomponent approach make up for the loss in yield.

Further we tried to explore the scope of the one-pot, twostep, three-component approach for pyrazole synthesis by varying aldehyde, 1,3-dicarbonyl, and diazo components separately. The strategy was found to work well with both electron withdrawing and electron donating aromatic aldehydes (Table 2). However, the yields of pyrazoles were lower in case of electron donating aromatic aldehydes (Table 2, entry 10 and 11). This was presumably due to the incomplete conversion of the electron donating aromatic aldehydes to aldehyde–acetyl acetone adducts at the very first step of the reaction. Heteroaromatic aldehydes such as quinoline-4-carboxaldehyde, N-ethyl carbazole-3-carboxaldehyde, and furfural gave high yields of pyrazoles (75–82%) using the one-pot, threecomponent approach (Table 2, entry 12–14).

The one-pot, three-component protocol was successful with aliphatic aldehydes such as *n*-butanal (4q) and *n*-hexanal (4r)yielding the desired pyrazoles in moderate yields (Table 2, entry 17, 18). However, phenyl acetaldehyde (40) and trimethylacetaldehyde (4p) did not lead to the pyrazole formation under our reaction conditions (Table 2, entry 15, 16). With phenyl acetaldehyde, the reaction mixture was too complex for purification. Purification of the reaction mixture derived from trimethylacetaldehyde yielded an oily compound (45%) the structure of which was assigned as 6aa by analyzing its ¹H NMR, ¹³C NMR, IR, and HRMS spectra (Figure 2). The compound 6aa seems to be derived from the protonation of EDA followed by its coupling with acetyl acetone. However, it was surprising that compound 6aa was not formed when a two component coupling of acetyl acetone and EDA was attempted under the same reaction conditions.

We, therefore, planned to synthesize pyrazoles by reacting the purified aliphatic aldehyde—acetyl acetone adducts **10a** and **1pa** with EDA. The piperidinium acetate catalyzed reaction of phenyl acetaldehyde (**40**) with acetyl acetone (**5a**) yielded **10a'** (Scheme 1). Since the C–C double bond and carbonyls are not conjugated in **10a'**, pyrazole formation did not occur with it. Despite many attempts, the trimethylacetaldehyde—acetyl acetone adduct **1pa** could not be isolated or characterized using either our piperidinium acetate catalyzed protocol or several other acid/base catalyzed methods commonly used for Knoevenagel condensation reactions. Therefore, the synthesis of the corresponding pyrazole could not be attempted from trimethylacetaldehyde.

Next, we started investigating the scope of the 1,3dicarbonyls in the one-pot, three component pyrazole synthesis. Acetyl acetone (5a), benzoyl acetone (5b), ethyl acetoacetate (5c), and dibenzoyl methane (5d) were taken as four different 1,3-dicarbonyls for the study. The one-pot, threecomponent protocol optimized for acetyl acetone did not work for the rest of the 1,3-dicarbonyls, **5b**, **5c**, and **5d**. In the case of benzoyl acetone (5b), the acetyl group was partially cleaved yielding a mixture of pyrazole and dihydropyrazoles, which could not be separated by column chromatography. Under our Table 2. Synthesis of Pyrazoles 3aaa–3gaj via One-Pot, Two-Step, Three-Component Reaction of Aldehydes 4a–s, 1,3-Dicarbonyls 5a–d, and Diazo-acetates 2a–c or Tosyl Hydrazones 2d–j



	aldehyde (4)		1,3-dicarbonyl (5)			diazo-ester or tosyl hydrazone (2)			
entry	compd no.	R	compd no.	\mathbb{R}^1	R ²	compd no.	R ³	pyrazole (3)	yield ^{a} of pyrazole (%)
1^b	4a	4-Cl-C ₆ H ₄	5a	Me	Me	2a	COOEt	3aaa	80
2^{b}	4b	4-Br-C ₆ H ₄	5a	Me	Me	2a	COOEt	3baa	77
3^b	4c	$4-CF_{3}-C_{6}H_{4}$	5a	Me	Me	2a	COOEt	3caa	80
4^b	4d	4-Cl-3-F-C ₆ H ₄	5a	Me	Me	2a	COOEt	3daa	81
5^b	4e	1-naphthyl	5a	Me	Me	2a	COOEt	3eaa	75
6^b	4f	2-naphthyl	5a	Me	Me	2a	COOEt	3faa	79
7^{b}	4g	$3-O_2N-C_6H_4$	5a	Me	Me	2a	COOEt	3gaa	83
8^b	4h	$4-O_2N-C_6H_4$	5a	Me	Me	2a	COOEt	3haa	85
9^b	4i	4-CN-C ₆ H ₄	5a	Me	Me	2a	COOEt	3iaa	81
10^{b}	4j	$3-4$ -methylenedioxy- C_6H_3	5a	Me	Me	2a	COOEt	3jaa	65
11^{b}	4k	$4-Me-C_6H_4$	5a	Me	Me	2a	COOEt	3kaa	71
12^{b}	41	quinolin-4-yl	5a	Me	Me	2a	COOEt	3laa	78
13^{b}	4m	9-ethyl-9H-carbazol-3-yl	5a	Me	Me	2a	COOEt	3maa	82
14^{b}	4n	2-furyl	5a	Me	Me	2a	COOEt	3naa	75
15^{b}	40	PhCH ₂	5a	Me	Me	2a	COOEt		f
16^{b}	4p	(CH ₃) ₃ C	5a	Me	Me	2a	COOEt		f
17^{b}	4q	$n-C_3H_7$	5a	Me	Me	2a	COOEt	3qaa	51
18^{b}	4r	<i>n</i> -C ₅ H ₁₁	5a	Me	Me	2a	COOEt	3raa	57
19 ^c	4a	4-Cl-C ₆ H ₄	5b	Me	Ph	2a	COOEt	3aba	78
20 ^c	4g	$3-O_2N-C_6H_4$	5c	Me	OEt	2a	COOEt	3gca	75
21 ^c	4i	$4-CN-C_6H_4$	5c	Me	OEt	2a	COOEt	3ica	71
22 ^c	4s	$3-F-C_6H_4$	5d	Ph	Ph	2a	COOEt	3sda	80
23^{b}	4g	$3-O_2N-C_6H_4$	5a	Me	Me	2b	COO ^t Bu	3gab	77
24^{b}	4i	$4-CN-C_6H_4$	5a	Me	Me	2b	COO ^t Bu	3iab	78
25 ^b	4g	$3-O_2N-C_6H_4$	5a	Me	Me	2c	COOBn	3gac	81
26^{b}	4i	4-CN-C ₆ H ₄	5a	Me	Me	2c	COOBn	3iac	75
27^d	4g	$3-O_2N-C_6H_4$	5a	Me	Me	2d	3-MeO-C ₆ H ₄	3gad	90 $(85)^e$
28 ^d	4g	$3-O_2N-C_6H_4$	5a	Me	Me	2e	$4-O_2N-C_6H_4$	3gae	85
29 ^d	4i	$4-CN-C_6H_4$	5a	Me	Me	2d	$3-MeO-C_6H_4$	3iad	89
30 ^d	4i	4-CN-C ₆ H ₄	5a	Me	Me	2f	3-Cl-4-O2N-C6H3	3iaf	90
31^{d}	4i	4-CN-C ₆ H ₄	5a	Me	Me	2e	$4-O_2N-C_6H_4$	3iae	88
32 ^d	4k	4-Me-C ₆ H ₄	5a	Me	Me	2e	$4-O_2N-C_6H_4$	3kae	85
33 ^d	4q	$n-C_3H_7$	5a	Me	Me	2g	$3-O_2N-C_6H_4$	4qag	70
34 ^d	4q	$n-C_3H_7$	5a	Me	Me	2h	2-furyl		f
35 ^d	4g	$3-O_2N-C_6H_4$	5a	Me	Me	2h	2-furyl		f
36 ^d	4g	$3-O_2N-C_6H_4$	5a	Me	Me	2i	2-thienyl		f
37 ^d	4g	$3-O_2N-C_6H_4$	5a	Me	Me	2j	9-ethyl-9H-carbazol-3-yl	3gaj	78
38 ^d	4g	$3-O_2N-C_6H_4$	5a	Me	Me	2k	$n-C_3H_7$		f

^{*a*}Isolated yield. ^{*b*}Reaction conditions: aldehyde (1 mmol), acetyl acetone (1 mmol), piperidinium acetate (20 mol %), solvent-free, stir, 10–30 min, then diazo-ester (1.01 mmol), DMSO (1 mL), 70 °C, 12 h. ^cReaction conditions: aldehyde (1 mmol), 1,3-dicarbonyl (1 mmol), piperidinium acetate (20 mol %), solvent-free, stir, 10–30 min, then EDA (1.01 mmol), K₂CO₃ (1.5 mmol), EtOH (10 mL), reflux, 24 h. ^{*d*}Reaction conditions: aldehyde (1 mmol), acetyl acetone (1 mmol), piperidinium acetate (20 mol %), solvent-free, stir, 10–30 min, then tosyl hydrazone (1.5 mmol), K₂CO₃ (3.0 mmol), MeOH (10 mL), reflux, 12 h. ^{*e*}Yield in parentheses is for gram scale (10 mmol scale) reaction. ^{*f*}Not formed.

optimized conditions (Table 2, footnote *b*), the acetyl group of ethyl acetoacetate (5c) was not cleaved, and the reaction yielded a mixture of inseparable diastereomers of dihydropyrazole 7gca. Similarly the benzoyl group of dibenzoyl methane (5d) was not cleaved yielding dihydropyrazoles 7ada and 7hda (Figure 3). These results indicated that water or piperidinium acetate were incapable of removing the acetyl (or benzoyl)

group from the products (7gca-7hda). We, therefore, used K_2CO_3 as a base in EtOH for the reaction and achieved high yields (71-80%) of desired pyrazoles **3aba-3sda** under standard conditions (Table 2, entry 19–22). The combination of K_2CO_3 and DMSO was not suitable for the reaction because it hydrolyzed the ester, and the acid thus obtained could not be purified by column chromatography.



Figure 2. Chemical structure of compound 6aa.

Next we tried to explore the scope of the reaction in terms of the diazo component. The three-component reaction of aldehyde, acetyl acetone, and diazo esters such as *tert*-butyl diazoacetate (**2b**) and benzyl diazoacetate (**2c**) proceeded successfully (Table 2, entry 23–26). Following the optimized protocol, a number of pyrazoles **3gab–3iac** were synthesized in high yields (75–81%).

Finally the scope of the pyrazole synthesis was studied by taking tosyl hydrazones as an alternative to diazo compounds (Table 2, entry 27-38).¹⁹ The use of tosyl hydrazones in the three-component reaction not only is exciting from a safety point of view but also extends the scope of the work toward a wide range of diazo compounds that are not commercially available. After screening several conditions, we found that refluxing the reaction mixture in MeOH using 3 equiv of K_2CO_3 as a base gave good yields of pyrazoles. Under basic reaction conditions (K₂CO₃) and heating, tosyl hydrazones were converted to corresponding diazo compounds, which reacted with aldehyde-acetyl acetone adducts. A series of substituted pyrazoles 3gad-3gaj were synthesized using the one-pot, three-component protocol in high yields (70-90%). In order to further demonstrate the advantage of this method, a gram scale synthesis of 3gad was performed under standard conditions. The desired pyrazole 3gad was obtained in 85% yield, which indicates that there is potential industrial application (Table 2, entry 27). The three-component reaction was successful with aliphatic aldehyde (n-butanal) yielding a high yield (70%) of the desired pyrazole 4qag (Table 2, entry 33). However, the reaction was not successful with tosyl hydrazone derived from aliphatic aldehyde (Table 2, entry 38). The reaction was also not successful with tosyl hydrazones derived from typical heteroaromatic aldehydes such as furfural (Table 2, entries 34 and 35) and 2-thenaldehyde (Table 2, entry 36). This was plausibly due to the fast decomposition of furfural tosyl hydrazones into highly reactive enynyl-ketones reported very recently.²⁰ Furthermore, high yield (78%) of the desired pyrazole 3gaj was obtained with tosyl hydrazone derived from 9-ethyl-9H-carbazole-3-carbaldehyde as another heteroaromatic aldehyde.

The high regioselectivity observed in our pyrazole synthesis is in accordance with previous literature reports involving 1,3dipolar cycloaddition reactions of electron deficient olefins with diazo compounds.^{15,16} It can be explained by considering atomic orbital coefficients of HOMO (diazo component)– LUMO (alkene) favored interactions expected for these type of



Figure 3. Chemical structures of dihydropyrazoles derived from threecomponent coupling of aldehyde, 1,3-dicarbonyl, and EDA under reaction conditions mentioned in footnote *b* of Table 2

1,3-dipolar cycloaddition reactions. In many ¹H NMR spectra of pyrazoles, methyl hydrogen atoms of the acetyl group appeared as broad signals. And in many ¹³C NMR spectra, C-3 and C-5 carbons of the pyrazole and carbonyl carbon were not resolved from the baseline. It is indeed due to the dynamic tautomeric forms that NH-pyrazole can adopt and is well documented in literature.^{17,21}

The structural assignment for pyrazoles 3aaa-3gaj and dihydropyrazoles 7gca-7hda was based on the expected direction of the 1,3-dipolar cycloaddition reaction of diazo compounds with electron deficient alkenes reported in literature.^{15,16} In order to give an unambiguous proof for the structural assignments, we attempted HMBC and 2D NOESY for several compounds (3kaa, 3gad, and 3gae). However, due to the dynamic tautomeric structures of the NH-pyrazoles (Scheme 2), these compounds did not give proper HMBC and 2D NOESY spectra. Furthermore, we attempted to collect single crystal X-ray analysis data for several pyrazoles, but unfortunately the diffraction patterns were not good enough. We, therefore, planned to eliminate the dynamic tautomerism of pyrazoles 3kaa, 3gad, and 3gae by reacting them with ethyl α -bromoacetate (Scheme 2). The structural assignments for these pyrazole derivatives (9kaaa, 9gada, and 9gaea) were made through their HMBC and 2D NOESY spectra. Finally we succeeded in getting a single crystal X-ray analysis of the pyrazole derivative 9gaea (Figure 4).

The structural characterization of pyrazole derivatives **9kaaa**, **9gada**, and **9gaea** reveals some interesting information. First, it confirms that the mode of the 1,3-dipolar cycloaddition reaction of diazo-acetates (2a-c), as well as aryl-diazomethanes derived from tosyl hydrazones (2d-j) toward aldehyde–acetyl acetone adducts is same. Second, electronic tuning of the tosyl hydrazone component (**3gad** and **3gae**) does not switch the regiochemical outcome of the reaction.

Formation of pyrazoles from the reaction of tosyl hydrazones with aldehyde–acetyl acetone adducts might be imagined to proceed without the intermediacy of corresponding aryl-diazomethanes. Such a stepwise addition–elimination reaction might give either a different regiomer or a mixture of regiomers. To get insight into such a possibility, (p-nitrophenyl)-diazomethane²² was prepared and reacted with 3-nitrobenzaldehyde–acetyl acetone adduct. After workup and purification, we got the same pyrazole **3gae** (92%). This and the regiospecificity of the reaction, therefore, indirectly prove





Scheme 2. Eliminating the Possibility of Dynamic Tautomers by Alkylating Pyrazoles 3kaa, 3gad, and 3gae by Ethyl α -Bromoacetate^a



^{*a*}Key ${}^{1}H-{}^{1}H$ (NOESY) correlations of the pyrazoles **9gada** and **9gaea** and ${}^{1}H-{}^{13}C$ (HMBC) correlations for the pyrazole **9kaaa** are shown by arrows.



Figure 4. Single crystal X-ray analysis of compound **9gaea** (CCDC ref. No. 1050199; for details, see Supporting Information).

the intermediacy of aryl-diazomethanes in the pyrazole synthesis from tosyl hydrazones.

Formation of the pyrazoles can be explained by a plausible mechanism as depicted in Scheme 3. EDA (or the aryl diazomethane generated *in situ* from tosyl hydrazone) undergoes a 1,3-dipolar cycloaddition reaction with alkene 1 leading to the formation of an intermediate 10, which isomerizes to 10'. Next water (or K_2CO_3) attacks the intermediate 10' leading to the formation of another intermediate 11, which loses one acetyl group to form a dihydropyrazole 12. Under aerobic conditions, the dihydropyrazole 12 aromatizes to pyrazole 3. Attempts to isolate the dihydropyrazoles 12 by performing reactions under nitrogen atmosphere failed. This indicated that dihydropyrazoles 12 were very much prone to aerobic oxidative aromatization when exposed to air.

The proposed mechanism depicted in Scheme 3 raises several questions. First it is reasonable to argue whether the acetyl group is lost from the initially formed five member ring (10) or from the $\alpha_{,\beta}$ -unsaturated compound itself. Second, is the additional acetyl group is necessary for the success of the





Scheme 4. Control Experiment: Isolation of the Initially Formed Five Member Adduct 7naa and Its Subsequent Conversion to Pyrazole 3naa



Scheme 5. Control Experiment: Preparation of Benzaldehyde–Acetone Adduct 1te and Its Reactions with EDA (2a) and Tosyl Hydrazone (2g)



pyrazole synthesis? In order to address the former query, we subjected the compound laa under three different reaction conditions: (a) piperidinium acetate (20 mol %), DMSO, 70 °C, 24 h; (b) piperidinium acetate (20 mol %), K₂CO₃ (150 mol %), EtOH, reflux, 24 h; (c) piperidinium acetate (20 mol %), K₂CO₃ (300 mol %), MeOH, reflux, 24 h. In all three reaction conditions, 1aa was almost completely recovered $(\geq 90\%)$. Next, we carried out a control reaction of furfuralacetyl acetone adduct 1na with EDA in anhydrous toluene under nitrogen atmosphere as depicted in Scheme 4. The initially formed five member adduct 7naa was isolated, and its treatment with K₂CO₃ (150 mol %) in EtOH yielded the desired pyrazole 3naa in 95% yield. Similarly the dyhydropyrazoles 7gca, 7ada, and 7hda were also converted to corresponding pyrazoles by treating them with K₂CO₃ (150 mol %) in EtOH. These experiments clearly support that the acetyl group is lost from the initially formed five member ring as depicted in Scheme 3.

In order to address the latter query regarding the necessity of the additional acetyl group, we carried out a few control experiments. First, benzaldehyde-acetone adduct **1te** was prepared and reacted with EDA as well as tosyl hydrazones (Scheme 5). Although formation of the desired pyrazole **1tea** was not observed (TLC and MS analysis) with EDA, the corresponding reaction with tosyl hydrazone gave a high yield of the corresponding pyrazole **3teg** (75%). These results suggest that the additional acetyl group is necessary for the success of pyrazole synthesis at least in the case of diazoacetates. Although we partially succeeded in synthesizing pyrazoles from aldehyde-acetone adduct **1te**, the overall reaction cannot be done in a one-pot fashion. Therefore, we conclude that an additional acetyl group is very much required in order to achieve a general one-pot, three-component synthesis of pyrazoles.

CONCLUSIONS

In conclusion, we have developed a one-pot protocol that affords excellent yields of highly substituted pyrazoles and several dihydropyrazoles from simple and inexpensive starting materials and catalysts, using the advantages of multicomponent reaction. This one-pot process does not require the purification of intermediates and eliminates the use of toxic transition metal based catalysts or oxidants. It generates two C-C and one C-N bonds through a cascade of several individual reactions and is mechanistically novel in that it involves the cleavage of an acetyl group for the pyrazole formation. A series of pyrazoles was synthesized using electron donating or withdrawing aromatic aldehydes, heteromatic aldehydes, 1,3-dicarbonyls, and diazo compounds in high yield. The direct use of tosyl hydrazones further extends the scope of the reaction and avoids handling of sensitive diazo compounds.

EXPERIMENTAL SECTION

General. The reagents, chemicals, and solvents were either purchased from commercial suppliers or prepared and purified by standard techniques. Column chromatography was carried out using silica gel 100–200 mesh. Infrared spectra were recorded using a FT-IR spectrophotometer, and values are reported in cm⁻¹. ¹H and ¹³C NMR spectra were recorded with 300 and 500 MHz NMR instruments with tertramethylsilane (TMS) as an internal standard. High-resolution mass spectra (ESI-HRMS) were recorded on ESI-QTOP mass spectrometer.

Typical Experimental Procedure of the One-Pot, Three-Component Pyrazole Synthesis (3aaa–3raa). In a 10 mL roundbottom flask, aldehyde (1 mmol), acetyl acetone (1 mmol), and

piperidinium acetate (0.2 mmol) were mixed, and reaction mixture was shaken under solvent-free conditions. The formation of aldehyde–acetyl acetone adduct was complete in about 10 min (monitored by TLC). Next EDA (1.01 mmol) and 1 mL of DMSO was added, and the reaction mixture was heated at 70 °C under open atmosphere until pyrazole formation was complete. Next the reaction mixture was diluted with dichloromethane (25 mL) and washed with brine (5 mL \times 3). The organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure to yield a crude reaction product. The crude was purified by silica-gel column chromatography using ethyl acetate-hexane as eluent in increasing polarity to yield the desired pyrazoles **3aaa-3raa**.

*Ethyl*² 3-Acetyl-4-(4-chlorophenyl)-1H-pyrazole-5-carboxylate, **3aaa**. A total of 234 mg (80%) of **3aaa** was obtained as a white solid, $R_f = 0.55$ (ethyl acetate/*n*-hexane, 3:7), mp 109–110 °C. IR (KBr, cm⁻¹): 3166, 2980, 1718, 1676, 1438, 1214, 1202. ¹H NMR (CDCl₃, 500 MHz) δ : 11.42 (bs, 1H), 7.40 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.4 Hz, 2H), 4.27 (q, J = 7.2 Hz, 2H), 2.37 (s, 3H), 1.21 (t, J =7.2 Hz, 3H). ¹³C NMR (CDCl₃, 75 MHz) δ : 191.8, 160.0, 134.2, 131.4, 129.2, 128.0, 125.5, 61.6, 28.2, 13.9. HRMS (ESI, Orbitrap): calcd for C₁₄H₁₄ClN₂O₃ [M + H]⁺ 293.06930; found 293.06847.

Ethyl 3-Acetyl-4-(4-bromophenyl)-1H-pyrazole-5-carboxylate, **3baa**. A total of 259 mg (77%) of **3baa** was obtained as a white solid, $R_f = 0.51$ (ethyl acetate/*n*-hexane, 3:7), mp 111–112 °C. IR (KBr, cm⁻¹): 3165, 2978, 1718, 1675, 1200, 1214. ¹H NMR (CDCl₃, 500 MHz) δ : 11.35 (bs, 1H), 7.55 (d, J = 7.8 Hz, 2H), 7.22 (d, J = 8.2Hz, 2H), 4.27 (q, J = 7.2 Hz, 2H), 2.39 (bs, 3H), 1.21 (t, J = 7.2 Hz, 3H). ¹³C NMR (CDCl₃, 75 MHz) δ : 187.5, 158.5, 131.7, 131.0, 129.7, 122.5, 61.6, 28.2, 13.9. HRMS (ESI, Orbitrap): calcd for C₁₄H₁₃BrN₂O₃Na [M + Na]⁺ 359.00072; found 359.00041.

Ethyl 3-Acetyl-4-(4-(trifluoromethyl)phenyl)-1H-pyrazole-5-carboxylate, **3caa**. A total of 261 mg (80%) of **3caa** was obtained as a white solid, $R_f = 0.45$ (ethyl acetate/*n*-hexane, 3:7), mp 111–112 °C. IR (KBr, cm⁻¹): 3248, 2988, 1714, 1335, 1221. ¹H NMR (CDCl₃, 300 MHz) δ : 11.51 (bs, 1H), 7.68 (d, J = 7.9 Hz, 2H), 7.48 (d, J = 7.9 Hz, 2H), 4.26 (q, J = 7.2 Hz, 2H), 2.41 (s, 3H), 1.19 (t, J = 7.2 Hz, 3H). ¹³C NMR (CDCl₃, 125 MHz) δ : 192.0, 159.7, 145.8, 136.0, 134.7, 130.5, 130.3 (q, J = 32.7 Hz), 127.3 (q, J = 272.5 Hz), 125.1, 124.6 (q, J = 3.6 Hz), 61.7, 28.0, 13.7. HRMS (ESI, Orbitrap): calcd for C₁₅H₁₄F₃N₂O₃ [M + H]⁺ 327.09565; found 327.09596.

Ethyl 3-Acetyl-4-(4-chloro-3-fluorophenyl)-1H-pyrazole-5-carboxylate, **3daa**. A total of 252 mg (81%) of **3daa** was obtained as a white solid, $R_f = 0.35$ (ethyl acetate/*n*-hexane, 3:7), mp 128–130 °C. IR (KBr, cm⁻¹): 3224, 1713, 1694, 1439, 1218. ¹H NMR (CDCl₃, 500 MHz) δ : 11.38 (bs, 1H), 7.42 (t, *J* = 7.9 Hz, 1H), 7.17 (dd, *J* = 1.8, 9.6 Hz, 1H), 7.07 (d, *J* = 8.2 Hz, 1H), 4.28 (q, *J* = 7.2 Hz, 2H), 2.44 (s, 3H), 1.22 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (CDCl₃, 125 MHz) δ : 192.0, 159.5, 158.3 (d, *J* = 247.9 Hz), 131.1(d, *J* = 7.2 Hz), 129.8, 126.8 (d, *J* = 2.7 Hz), 124.2, 120.9 (d, *J* = 17.3 Hz), 118.7 (d, *J* = 21.7 Hz), 61.8, 28.0, 13.8. HRMS (ESI, Orbitrap): calcd for C₁₄H₁₃ClFN₂O₃ [M + H]⁺ 311.05987; found 311.05984.

Ethyl 3-Acetyl-4-(*naphthalen-1-yl*)-1*H*-pyrazole-5-carboxylate, **3eaa**. A total of 231 mg (75%) of **3eaa** was obtained as a white solid, $R_f = 0.48$ (ethyl acetate/*n*-hexane, 3:7), mp 103–104 °C. IR (KBr, cm⁻¹): 3219, 1730, 1682, 1440, 1235. ¹H NMR (CDCl₃, 300 MHz) δ : 11.70 (bs, 1H), 7.93 (t, *J* = 7.5 Hz, 2H), 7.57–7.40 (m, SH), 4.05 (q, *J* = 7.2 Hz, 2H), 2.00 (s, 3H), 0.83 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (CDCl₃, 125 MHz) δ : 190.4, 160.6, 133.4, 132.5, 129.0, 128.8, 128.4, 127.7, 126.4, 125.9, 125.1, 125.0, 124.6, 61.0, 27.8, 13.4. HRMS (ESI, Orbitrap): calcd for C₁₈H₁₇N₂O₃ [M + H]⁺ 309.12392; found 309.12316.

Ethyl 3-Acetyl-4-(naphthalen-2-yl)-1H-pyrazole-5-carboxylate, **3faa.** A total of 243 mg (79%) of **3faa** was obtained as a white solid, $R_f = 0.51$ (ethyl acetate/*n*-hexane, 3:7), mp 103–104 °C. IR (KBr, cm⁻¹): 3248, 2982, 1706, 1690, 1423, 1216. ¹H NMR (CDCl₃, 500 MHz) δ : 11.44 (bs, 1H), 7.94–7.87 (m, 2H), 7.84–7.80 (m, 2H), 7.53–7.48 (m, 2H), 7.45 (dd, J = 1.4, 8.4 Hz, 1H), 4.22 (q, J = 7.2 Hz, 2H), 2.27 (s, 3H), 1.10 (t, J = 7.2 Hz, 3H). ¹³C NMR (CDCl₃, 125 MHz) δ : 191.4, 160.5, 132.9, 132.8, 129.3, 128.2, 128.0, 127.8, 127.7, 127.4, 126.8, 126.4, 126.3, 61.3, 28.3, 13.8. HRMS (ESI, Orbitrap): calcd for $C_{18}H_{17}N_2O_3~[M\,+\,H]^+$ 309.12392; found 309.12302.

Ethyl 3-Acetyl-4-(3-nitrophenyl)-1*H*-pyrazole-5-carboxylate, **3gaa**. A total of 252 mg (83%) of **3gaa** was obtained as a white solid, $R_f = 0.35$ (ethyl acetate/*n*-hexane, 3:7), mp 125–126 °C. IR (KBr, cm⁻¹): 3267, 2996, 1689, 1528, 1349, 1228. ¹H NMR (CDCl₃, 500 MHz) δ : 11.65 (bs, 1H), 8.27 (d, J = 8.4 Hz, 1H), 8.24 (s, 1H), 7.70 (d, J = 7.6 Hz, 1H), 7.60 (t, J = 7.9 Hz, 1H), 4.27 (q, J = 7.2 Hz, 2H), 2.53 (s, 3H), 1.17 (t, J = 7.2 Hz, 3H). ¹³C NMR (CDCl₃, 75 MHz) δ : 192.8, 159.2, 147.6, 136.5, 132.4, 128.4, 125.8, 123.8, 122.9, 61.9, 27.8, 13.7. HRMS (ESI, Orbitrap): calcd for C₁₄H₁₃N₃NaO₅ [M + Na]⁺ 326.07529; found 326.07549.

Ethyl 3-Acetyl-4-(4-nitrophenyl)-1*H*-pyrazole-5-carboxylate, **3haa**. A total of 258 mg (85%) of **3haa** was obtained as a white solid, $R_f = 0.34$ (ethyl acetate/*n*-hexane, 3:7), mp 141–142 °C. IR (KBr, cm⁻¹): 3161, 2979, 1721, 1677, 1603, 1517, 1346, 1214. ¹H NMR (CDCl₃, 300 MHz) δ : 11.44 (bs, 1H), 8.29 (d, *J* = 8.3 Hz, 2H), 7.53 (d, *J* = 8.3 Hz, 2H), 4.28 (q, *J* = 7.3 Hz, 2H), 2.50 (s, 3H), 1.21 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (CDCl₃, 75 MHz) δ : 192.6, 159.2, 147.5, 137.9, 131.2, 124.2, 122.7, 61.9, 27.8, 13.8. HRMS (ESI, Orbitrap): calcd for C₁₄H₁₄N₃O₅ [M + H]⁺ 304.09335; found 304.09291.

Ethyl 3-Acetyl-4-(4-cyanophenyl)-1H-pyrazole-5-carboxylate, **3iaa**. A total of 229 mg (81%) of **3iaa** was obtained as a white solid, $R_f = 0.40$ (ethyl acetate/*n*-hexane, 3:7), mp 158–160 °C. IR (KBr, cm⁻¹): 3224, 2924, 2230, 1731, 1693, 1440, 1227. ¹H NMR (CDCl₃, 500 MHz) δ : 11.84 (bs, 1H), 7.71 (d, J = 8.4 Hz, 2H), 7.47 (d, J = 8.4 Hz, 2H), 4.27 (q, J = 7.2 Hz, 2H), 2.49 (s, 3H), 1.18 (t, J =7.3 Hz, 3H). ¹³C NMR (CDCl₃, 75 MHz) δ : 192.5, 159.3, 146.5, 136.0, 134.8, 131.3, 130.9, 124.5, 118.7, 111.6, 61.8, 27.8, 13.7. HRMS (ESI, Orbitrap): calcd for C₁₅H₁₄N₃O₃ [M + H]⁺ 284.10352; found 284.10226.

Ethyl 3-Acetyl-4-(benzo[d][1,3]dioxol-5-yl)-1H-pyrazole-5-carboxylate, **3jaa**. A total of 196 mg (65%) of **3jaa** was obtained as a white solid, $R_f = 0.30$ (ethyl acetate/n-hexane, 3:7), mp 118–119 °C. IR (KBr, cm⁻¹): 3198, 2922, 1715, 1693, 1508, 1418, 1219. ¹H NMR (CDCl₃, 500 MHz) δ : 11.48 (bs, 1H), 6.89 (d, J = 7.9 Hz, 1H), 6.83 (s, 1H), 6.81 (d, J = 7.9 Hz, 1H), 6.04 (s, 2H), 4.30 (q, J = 7.2 Hz, 2H), 2.34 (s, 3H), 1.26 (t, J = 7.2 Hz, 3H). ¹³C NMR (CDCl₃, 125 MHz) δ : 191.3, 160.4, 147.6, 147.2, 126.5, 124.0, 123.7, 110.6, 107.0, 101.2, 61.3, 28.2, 13.9. HRMS (ESI, Orbitrap): calcd for C₁₅H₁₅N₂O₅ [M + H]⁺ 303.09810; found 303.09823.

Ethyl 3-Acetyl-4-p-tolyl-1H-pyrazole-5-carboxylate, **3kaa**. A total of 193 mg (71%) of **3kaa** was obtained as a light green oil, $R_f = 0.45$ (ethyl acetate/*n*-hexane, 3:7). IR (KBr, cm⁻¹): 3274, 2926, 1718, 1440, 1215. ¹H NMR (CDCl₃, 300 MHz) δ : 11.24 (bs, 1H), 7.25–7.20 (m, 4H), 4.25 (q, J = 7.2 Hz, 2H), 2.41 (s, 3H), 2.25 (s, 3H), 1.21 (t, J = 7.2 Hz, 3H). ¹³C NMR (CDCl₃, 75 MHz) δ : 191.2, 160.5, 143.5, 138.6, 138.0, 129.8, 128.6, 127.6, 127.1, 61.2, 28.3, 21.3, 13.9. HRMS (ESI, Orbitrap): calcd for C₁₅H₁₇N₂O₃ [M + H]⁺ 273.12392; found 273.12422.

Ethyl 3-Acetyl-4-(quinolin-4-yl)-1H-pyrazole-5-carboxylate, 3laa. A total of 241 mg (78%) of **3laa** was obtained as a white solid, $R_f = 0.32$ (ethyl acetate/*n*-hexane, 3:7), mp 250–251 °C. IR (KBr, cm⁻¹): 3424, 1722, 1692, 1599, 1206. ¹H NMR (CDCl₃ + DMSO-*d*₆, 300 MHz) δ : 14.50 (bs, 1H), 8.94 (d, *J* = 4.5 Hz, 1H), 8.17 (d, *J* = 8.3 Hz, 1H), 7.72–7.67 (m, 1H), 7.47–7.40 (m, 2H), 7.31 (d, *J* = 4.5 Hz, 1H), 3.99 (q, *J* = 7.2 Hz, 2H), 2.44 (s, 3H), 0.73 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (CDCl₃ + DMSO-*d*₆, 125 MHz) δ : 190.4, 159.5, 148.5, 146.9, 139.2, 130.2, 129.7, 128.6, 128.3, 126.9, 125.6, 121.4, 119.9, 119.3, 60.0, 26.6, 12.4. HRMS (ESI, Orbitrap): calcd for C₁₇H₁₆N₃O₃ [M + H]⁺ 310.1192; found 310.1194.

Ethyl 3-Acetyl-4-(9-ethyl-9H-carbazol-3-yl)-1H-pyrazole-5-carboxylate, **3maa**. A total of 308 mg (82%) of **3maa** was obtained as a white solid, $R_f = 0.50$ (ethyl acetate/*n*-hexane, 3:7), mp 172–173 °C. IR (KBr, cm⁻¹): 3247, 3049, 2974, 1712, 1683, 1443, 1231, 1207. ¹H NMR (CDCl₃, 500 MHz) δ : 8.07 (d, J = 8.1 Hz, 1H), 8.06 (s, 1H), 7.52–7.40 (m, 4H), 7.23 (t, J = 7.8 Hz, 1H), 4.42 (q, J = 7.2 Hz, 2H), 4.23 (q, J = 7.2 Hz, 2H), 2.84 (bs, 1H), 2.21 (s, 3H), 1.48 (t, J = 7.2 Hz, 3H), 1.14 (t, J = 7.2 Hz, 3H). ¹³C NMR (CDCl₃, 125 MHz) δ : 191.3, 160.9, 140.2, 139.7, 128.0, 127.7, 125.8, 122.7, 122.5, 122.1,

120.7, 120.5, 118.9, 108.5, 107.8, 61.1, 37.7, 28.4, 13.9, 13.8. HRMS (ESI, Orbitrap): calcd for $C_{22}H_{22}N_3O_3\ [M+H]^+$ 376.16612; found 376.16634.

Ethyl 3-Acetyl-4-(furan-2-yl)-1H-pyrazole-5-carboxylate, 3naa. A total of 186 mg (75%) of **3naa** was obtained as a pale yellow oil, $R_f = 0.43$ (ethyl acetate/*n*-hexane, 3:7). IR (neat, cm⁻¹): 3247, 2983, 1727, 1694, 1441, 1229, 1211. ¹H NMR (CDCl₃, 500 MHz) δ : 11.70 (bs, 1H), 7.56 (d, J = 1.2 Hz, 1H), 6.76 (d, J = 3.4 Hz, 1H), 6.56–6.54 (m, 1H), 4.36 (q, J = 7.2 Hz, 2H), 2.44 (s, 3H), 1.32 (t, J = 7.2 Hz, 3H). ¹³C NMR (CDCl₃, 125 MHz) δ : 191.4, 160.0, 144.9, 142.8, 142.6, 137.9, 115.5, 112.5, 111.3, 61.6, 27.9, 13.9. HRMS (ESI, Orbitrap): calcd for C₁₂H₁₃N₂O₄ [M + H]⁺ 249.08753; found 249.08781.

Ethyl 5-Acetyl-4-propyl-1H-pyrazole-3-carboxylate, **3qaa**. A total of 114 mg (51%) of **3qaa** was obtained as a pale oil, $R_f = 0.50$ (ethyl acetate/*n*-hexane, 3:7). IR (neat, cm⁻¹): 3268, 2928, 2869, 1723, 1688, 1455, 1208. ¹H NMR (CDCl₃, 300 MHz) δ : 12.07 (bs, 1H), 4.42 (q, *J* = 7.2 Hz, 2H), 3.05 (t, *J* = 7.4 Hz, 2H), 2.64 (s, 3H), 1.62–1.54 (m, 2H), 1.41 (t, *J* = 7.2 Hz, 3H), 0.94 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (CDCl₃, 75 MHz) δ : 194.7, 160.1, 148.5, 132.9, 128.4, 61.4, 27.7, 25.3, 23.8, 14.1, 13.8. HRMS (ESI, Orbitrap): calcd for C₁₁H₁₇N₂O₃ [M + H]⁺ 225.1239; found 225.1257.

Ethyl 5-Acetyl-4-pentyl-1H-pyrazole-3-carboxylate, **3raa**. A total of 143 mg (57%) of **3raa** was obtained as a pale oil, $R_f = 0.35$ (ethyl acetate/*n*-hexane, 3:7). IR (neat, cm⁻¹): 3267, 2957, 1722, 1686, 1538, 1224. ¹H NMR (CDCl₃, 500 MHz) δ : 10.77 (bs, 1H), 4.42 (q, *J* = 7.2 Hz, 2H), 3.04 (t, *J* = 7.8 Hz, 2H), 2.60 (s, 3H), 1.41 (t, *J* = 7.2 Hz, 3H), 1.36–1.29 (m, 6H), 0.89 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (CDCl₃, 125 MHz) δ : 194.6, 160.1, 128.8, 61.4, 31.8, 30.3, 27.7, 23.5, 22.4, 14.2, 14.9. HRMS (ESI, Orbitrap): calcd for C₁₃H₂₁N₂O₃ [M + H]⁺ 253.1552; found 253.1561.

Experimental Procedure of the Synthesis of Compound 6aa. The typical one-pot, three-component synthetic protocol used for the pyrazoles **3aaa–3raa** was also used for the synthesis of compound **6aa.** Trimethylacetaldehyde was used as the aldehyde component, EDA as the diazo component, and acetyl acetone as 1,3-dicarbonyl component.

Ethyl 2-(2-(2,4-*Dioxopentan-3-ylidene*)*hydrazinyl*)*acetate*, **6aa**. A total of 96 mg (45%) of **6aa** was obtained as a red colored oil, $R_f = 0.45$ (ethyl acetate/*n*-hexane, 3:7). IR (neat, cm⁻¹): 3449, 2981, 2933, 1748, 1672, 1629, 1510, 1361, 1207. ¹H NMR (CDCl₃, 500 MHz) δ : 13.23 (bs, 1H), 4.39 (d, *J* = 4.7 Hz, 2H), 4.27 (q, *J* = 7.2 Hz, 2H), 2.53 (s, 3H), 2.32 (s, 3H), 1.32 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (CDCl₃, 75 MHz) δ : 197.1, 196.9, 168.1, 134.2, 61.8, 54.1, 31.3, 26.2, 14.1. HRMS (ESI, Orbitrap): calcd for C₉H₁₅N₂O₄ [M + H]⁺ 215.1032; found 215.1032.

Experimental Procedure of the Synthesis of Phenyl Acetaldehyde–Acetyl Acetone Adduct (10a'). In a 10 mL round-bottom flask, phenyl acetaldehyde (1 mmol), acetyl acetone (1 mmol), and piperidinium acetate (0.2 mmol) were mixed, and the reaction mixture was shaken under solvent-free conditions. After the formation of the aldehyde–acetyl acetone adduct was complete (TLC), the reaction mixture was directly purified by silica-gel column chromatography using ethyl acetate–hexane as eluent in increasing polarity to yield the **10a'**.

A total of 192 mg (95%) of **10a**' was obtained as a pale yellow oil, $R_f = 0.55$ (ethyl acetate/*n*-hexane, 3:7), IR (neat, cm⁻¹): 3423, 3061, 2926, 1709, 1601, 1413, 1204. ¹H NMR (CDCl₃, 500 MHz) δ : 7.43 (dd, J = 1.3, 7.5 Hz, 2H), 7.35 (t, J = 7.5 Hz, 2H), 7.27 (tt, J = 1.2, 7.3 Hz, 1H), 6.76 (d, J = 16.2 Hz, 1H), 6.43 (d, J = 16.2 Hz, 1H), 2.22 (s, 6H). ¹³C NMR (CDCl₃, 125 MHz) δ : 191.1, 137.0, 134.2, 128.6, 127.6, 126.0, 122.7, 111.3, 24.2. HRMS (ESI, Orbitrap): calcd for C₁₃H₁₃NaO₂ [M + Na]⁺ 224.08132; found 224.08015.

Typical Experimental Procedure of the One-Pot, Three-Component Dihydropyrazole Synthesis (7gca-7hda). The protocol used for the synthesis of pyrazoles 3aaa-3raa was used for the synthesis of dihydropyrazoles 7gca-7hda.

Diethyl 5-Acetyl-4-(3-nitrophenyl)-4,5-dihydro-1H-pyrazole-3,5dicarboxylate, **7gca**. A total of 302 mg (80%) of 7gca (mixture of inseparable diastereomers in 1:5 ratio) was obtained as an yellow oil, $R_{\rm f} = 0.34$ (ethyl acetate/*n*-hexane, 3:7). IR (KBr, cm⁻¹): 3340, 2984, 1724, 1532, 1350, 1230. ¹H NMR (CDCl₃, 500 MHz) of the major diastereomer δ : 8.16 (dd, J = 1.9, 9.3 Hz, 1H), 8.06 (s, 1H), 7.54–7.44 (m, 2H), 7.19 (s, 1H), 5.37 (d, J = 1.3 Hz, 1H), 4.22–4.10 (m, 4H); 3.84–3.48 (m, 1H) 3.70–3.63 (m, 1H), 2.32 (s, 3H), 1.21 (t, J = 7.2 Hz, 3H), 0.78 (t, J = 7.2 Hz, 3H). ¹³C NMR (CDCl₃, 125 MHz) δ : 199.3, 196.7, 167.9, 166.4, 160.5, 148.2, 144.0, 137.7, 136.4, 134.5, 130.1, 129.6, 123.6, 122.9, 85.6, 63.7, 62.8, 61.5, 54.9, 53.5, 28.0, 25.0, 13.8, 13.3. HRMS (ESI, Orbitrap): calcd for C₁₇H₂₀N₃O₇ [M + H]⁺ 378.13013; found 378.13112.

Ethyl 5,5-Dibenzoyl-4-(4-chlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxylate, **7ada**. A total of 339 mg (85%) of 7ada was obtained as a white solid, $R_f = 0.50$ (ethyl acetate/*n*-hexane, 3:7), mp 160–161 °C. IR (KBr, cm⁻¹): 3350, 1682, 1668, 1595, 1230. ¹H NMR (CDCl₃, 500 MHz) δ : 7.84 (dd, J = 1.0, 8.4 Hz, 2H), 7.62 (dd, J = 1.0, 8.4 Hz, 2H), 7.50 (tt, J = 1.0, 7.5 Hz, 1H), 7.41–7.36 (m, 3H), 7.30 (bs, 1H), 7.22 (t, J = 8.4 Hz, 2H), 7.00 (d, J = 8.5 Hz, 2H), 6.92 (d, J = 8.5 Hz, 2H), 5.90 (d, J = 1.2 Hz, 1H), 4.22–4.10 (m, 2H), 1.21 (t, J = 7.2 Hz, 3H). ¹³C NMR (CDCl₃, 125 MHz) δ : 193.9, 190.3, 160.8, 146.0, 134.7, 134.2, 134.1, 133.8, 132.7, 130.8, 129.3, 129.1, 129.0, 128.4, 88.4, 61.4, 55.3, 13.9. HRMS (ESI, Orbitrap): calcd for C₂₆H₂₂ClN₂O₄ [M + H]⁺ 461.12681; found 461.12763.

Ethyl 5,5-*Dibenzoyl-4-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole-3-carboxylate,* **7hda.** A total of 372 mg (91%) of 7hda was obtained as a white solid, $R_f = 0.40$ (ethyl acetate/*n*-hexane, 3:7), mp 161–162 °C. IR (KBr, cm⁻¹): 3327, 1679, 1596, 1526, 1350, 1232. ¹H NMR (CDCl₃, 300 MHz) δ : 7.87 (d, J = 8.9 Hz, 2H), 7.83 (d, J 7.7 Hz, 2H), 7.62 (d, J = 7.6 Hz, 2H), 7.53 (t, J = 7.4 Hz, 1H), 7.43–7.38 (m, 4H), 7.25–7.16 (m, 4H), 6.01 (s, 1H), 4.24–4.07 (m, 2H), 1.22 (t, J = 7.2Hz, 3H). ¹³C NMR (CDCl₃, 75 MHz) δ : 193.5, 189.8, 160.6, 147.2, 144.9, 141.7, 134.4, 134.0, 133.8, 130.4, 129.3, 129.2, 129.0, 128.6, 123.3, 88.8, 61.6, 55.3, 13.9. HRMS (ESI, Orbitrap): calcd for C₂₆H₂₂N₃O₆ [M + H]⁺ 472.15086; found 472.15069.

Typical Experimental Procedure of the One-Pot, Three-Component Pyrazole Synthesis (3aba–3sda). In a 25 mL roundbottom flask, aldehyde (1 mmol), 1,3-dicarbonyl compound (1 mmol), and piperidinium acetate (0.2 mmol) were mixed, and the reaction mixture was shaken under solvent-free conditions. The formation of aldehyde–1,3-dicarbonyl adduct was complete in about 10–30 min (monitored by TLC). Next EDA (1.01 mmol), K₂CO₃ (1.5 mmol), and 10 mL of EtOH was added, and the reaction mixture was refluxed in open air until pyrazole formation was complete (24 h). Next the reaction mixture was concentrated and purified directly by silica-gel column chromatography using ethyl acetate–hexane as eluent in increasing polarity to yield the desired the pyrazoles **3aba–3sda**.

Ethyl 5-*Benzoyl*-4-(4-*chlorophenyl*)-1*H*-*pyrazole*-3-*carboxylate*, **3aba**. A total of 277 mg (78%) of **3aba** was obtained as a white solid, $R_f = 0.40$ (ethyl acetate/*n*-hexane, 1:3), mp 136–138 °C. IR (KBr, cm⁻¹): 3189, 2923, 1726, 1652, 1450, 1229. ¹H NMR (CDCl₃, 300 MHz) δ : 11.92 (bs, 1H), 7.89 (d, *J* = 6.5 Hz, 2H), 7.51 (t, *J* = 6.5 Hz, 1H), 7.40–7.17 (m, 6H), 4.32 (q, *J* = 6.9 Hz, 2H), 1.23 (t, *J* = 6.9 Hz, 3H). ¹³C NMR (CDCl₃, 75 MHz) δ : 187.8, 159.7, 136.5, 133.8, 133.2, 131.7, 130.2, 128.8, 128.1, 127.7, 126.6, 61.7, 13.9. HRMS (ESI, Orbitrap): calcd for C₁₉H₁₆ClN₂O₃ [M + H]⁺ 355.08495; found 355.08566.

Diethyl 4-(3-Nitrophenyl)-1H-pyrazole-3,5-dicarboxylate, **3gca**. A total of 250 mg (75%) of **3gca** was obtained as a white solid, $R_f = 0.40$ (ethyl acetate/*n*-hexane, 2:3), mp 174–176 °C. IR (KBr, cm⁻¹): 3117, 2929, 1732, 1533, 1349. ¹H NMR (CDCl₃, 500 MHz) δ : 8.25 (d, J = 8.2 Hz, 1H), 8.21 (s, 1H), 7.68 (d, J = 7.6 Hz, 1H), 7.55 (t, J = 7.8 Hz, 1H), 4.67 (bs, 1H), 4.24 (q, J = 7.2 Hz, 4H), 1.16 (t, J = 7.2 Hz, 6H). ¹³C NMR (CDCl₃, 75 MHz) δ : 160.4, 147.3, 137.6, 136.7, 132.6, 128.1, 125.6, 124.9, 122.6, 61.6, 13.7. HRMS (ESI, Orbitrap): calcd for C₁₅H₁₆N₃O₆ [M + H]⁺ 334.10391; found 334.10410.

Diethyl 4-(4-Cyanophenyl)-1H-pyrazole-3,5-dicarboxylate, **3ica**. A total of 222 mg (71%) of **3ica** was obtained as a white solid, $R_f = 0.33$ (ethyl acetate/*n*-hexane, 2:3), mp 174–175 °C. IR (KBr, cm⁻¹): 3440, 2925, 1732, 1606, 1538, 1440, 1281. ¹H NMR (CDCl₃, 500 MHz) δ : 11.53 (bs, 1H), 7.68 (d, J = 7.9 Hz, 2H), 7.48 (d, J = 7.9 Hz, 2H), 4.28 (q, J = 7.1 Hz, 4H), 1.20 (t, J = 7.1 Hz, 6H). ¹³C NMR (CDCl₃, 75 MHz) δ : 159.8, 137.3, 135.8, 131.1, 131.0, 125.9, 118.7,

111.6, 61.7, 13.8. HRMS (ESI, Orbitrap): calcd for $C_{16}H_{16}N_3O_4$ [M + H]⁺ 314.11408; found 314.11451.

Ethyl 5-Benzoyl-4-(3-fluorophenyl)-1H-pyrazole-3-carboxylate, **3sda.** A total of 270 mg (80%) of **3sda** was obtained as a white solid, $R_f = 0.45$ (ethyl acetate/*n*-hexane, 1:3), mp 138–140 °C. IR (KBr, cm⁻¹): 3222, 2992, 1709, 1654, 1577, 1431, 1236. ¹H NMR (CDCl₃, 500 MHz) δ : 12.17 (bs, 1H), 7.98–7.77 (m, 2H), 7.49 (t, J =7.2 Hz, 1H), 7.35 (t, J = 7.3 Hz, 2H), 7.26–7.20 (m, 1H), 7.10–7.01 (m, 2H), 6.97 (t, J = 7.2 Hz, 1H), 4.30 (q, J = 7.1 Hz, 2H), 1.22 (t, J =7.1 Hz, 3H). ¹³C NMR (CDCl₃, 125 MHz) δ : 187.7, 162.9 (d, J =245.2 Hz), 159.8, 136.4, 133.1, 132.5 (d, J = 8.2 Hz), 130.0, 129.0, 128.9 (d, J = 9.1 Hz), 126.3, 126.2, 117.5 (d, J = 22.7 Hz), 114.7 (d, J =20.9 Hz), 61.7, 13.7. HRMS (ESI, Orbitrap): calcd for C₁₉H₁₆FN₂O₃ [M + H]⁺ 339. 1145; found 339. 1145.

Typical Experimental Procedure of the One-Pot, Three-Component Pyrazole Synthesis (3gab–3iac). The protocol used for the synthesis of pyrazoles 3aaa–3raa was used for the synthesis of compounds 3gab–3iac.

tert-Butyl 5-Acetyl-4-(3-nitrophenyl)-1H-pyrazole-3-carboxylate, **3gab.** A total of 255 mg (77%) of **3gab** was obtained as a white solid, $R_f = 0.40$ (ethyl acetate/*n*-hexane, 3:7), mp 150–151 °C. IR (KBr, cm-1): 3213, 2981, 1725, 1684, 1524, 1349, 1234, 1157. ¹H NMR (CDCl₃, 500 MHz) δ : 11.80 (bs, 1H), 8.25 (d, J = 8.2 Hz, 1H), 8.21 (s, 1H), 7.67 (d, J = 7.8 Hz, 1H), 7.57 (t, J = 7.9 Hz, 1H), 2.60 (bs, 3H), 1.36 (s, 9H). ¹³C NMR (CDCl₃, 125 MHz) δ : 193.5, 158.4, 147.5, 136.5, 132.9, 128.3, 125.5, 123.2, 122.6, 84.0, 27.8 (2C). HRMS (ESI, Orbitrap): calcd for C₁₆H₁₈N₃O₅ [M + H]⁺ 332.1247; found 332.1217.

tert-Butyl 5-Acetyl-4-(4-cyanophenyl)-1H-pyrazole-3-carboxylate, **3iab**. A total of 243 mg (78%) of **3iab** was obtained as a white solid, $R_{\rm f}$ = 0.45 (ethyl acetate/*n*-hexane, 3:7), mp 184–185 °C. IR (KBr, cm-1): 3213, 2978, 2236, 1716, 1692, 1223, 1157. ¹H NMR (CDCl₃, 500 MHz) δ : 11.90 (bs, 1H), 7.68 (d, *J* = 8.2 Hz, 2H), 7.44 (d, *J* = 8.2 Hz, 2H), 2.56 (bs, 3H), 1.36 (s, 9H). ¹³C NMR (CDCl₃, 75 MHz) δ : 193.2, 158.3, 136.6, 132.9, 131.2, 130.9, 127.7, 123.9, 118.8, 111.2, 83.8, 27.8 (2C). HRMS (ESI, Orbitrap): calcd for C₁₇H₁₈N₃O₃ [M + H]⁺ 312.1348; found 312.1338.

Benzyl 5-Acetyl-4-(3-nitrophenyl)-1H-pyrazole-3-carboxylate, **3gac.** A total of 296 mg (81%) of **3gac** was obtained as a white solid, $R_{\rm f} = 0.35$ (ethyl acetate/*n*-hexane, 3:7), mp 164–165 °C. IR (KBr, cm-1): 3234, 2926, 1731, 1685, 1525, 1350, 1188. ¹H NMR (CDCl₃, 500 MHz) δ : 11.90 (bs, 1H), 8.16 (d, J = 7.3 Hz, 1H), 8.15 (s, 1H), 7.61 (d, J = 7.6 Hz, 1H), 7.47 (t, J = 7.6 Hz, 1H), 7.32–7.24 (m, 3H), 7.09 (d, J = 7.0 Hz, 2H), 5.18 (s, 2H), 2.52 (bs, 3H). ¹³C NMR (CDCl₃, 75 MHz) δ : 192.8, 159.1, 147.4, 136.3, 133.8, 132.3, 128.7, 128.5, 128.4, 128.3, 125.3, 123.9, 122.8, 67.7, 27.8. HRMS (ESI, Orbitrap): calcd for C₁₉H₁₆N₃O₅ [M + H]⁺ 366.1090; found 366.1083.

Benzyl 5-Acetyl-4-(4-cyanophenyl)-1H-pyrazole-3-carboxylate, **3iac.** A total of 259 mg (75%) of **3iac** was obtained as a white solid, $R_f = 0.30$ (ethyl acetate/*n*-hexane, 3:7), mp 180–181 °C. IR (KBr, cm-1): 3448, 3205, 2923, 2229, 1734, 1666, 1446, 1223. ¹H NMR (CDCl₃, 500 MHz) δ : 11.78 (bs, 1H), 7.56 (d, J = 8.1 Hz, 2H), 7.38–7.30 (m, 6H), 7.08 (d, J = 6.8 Hz, 2H), 5.18 (s, 2H), 2.48 (bs, 3H). ¹³C NMR (CDCl₃, 125 MHz) δ : 194.3, 159.1, 135.9, 134.0, 131.3, 130.8, 128.8, 128.5, 128.3, 126.9, 124.6, 118.6, 111.6, 67.6, 27.8. HRMS (ESI, Orbitrap): calcd for C₂₀H₁₆N₃O₃ [M + H]⁺ 346.1192; found 346.1187.

Typical Experimental Procedure for the One-Pot, Three-Component Synthesis of Pyrazole (3gad–3gaj). In a 25 mL round-bottom flask, aldehyde (1 mmol), acetyl acetone (1 mmol), and piperidinium acetate (0.2 mmol) were mixed, and the reaction mixture was shaken under solvent-free conditions. The formation of the aldehyde–acetyl acetone adduct was complete in about 10 min (monitored by TLC). Next tosyl hydrazone (1.5 mmol), K_2CO_3 (3.0 mmol), and 10 mL of MeOH was added, and the reaction mixture was refluxed in open atmosphere until pyrazole formation was complete (12 h). Next the reaction mixture was concentrated and extracted with ethyl acetate/water. Next the organic layer was dried over anhydrous sodium sulfate, concentrated, and purified directly by silica-gel column

chromatography using ethyl acetate-hexane as eluent in increasing polarity to yield the desired the pyrazoles **3gad-3gaj**.

1-(3-(3-Methoxyphenyl)-4-(3-nitrophenyl)-1H-pyrazol-5-yl)ethanone, **3gad**. A total of 303 mg (90%) of **3gad** was obtained as a pale yellow solid, $R_f = 0.50$ (ethyl acetate/*n*-hexane, 1:1), mp 256–258 °C. IR (KBr, cm⁻¹): 3236, 3067, 2939, 1689, 1532, 1348, 1230, 1156. ¹H NMR (CDCl₃ + DMSO-*d*₆, 300 MHz) δ : 8.20–8.13 (m, 2H), 7.62–7.49 (m, 2H), 7.20 (t, *J* = 8.5 Hz, 1H), 6.90–6.80 (m, 3H), 3.68 (s, 3H), 2.60 (bs, 3H). ¹³C NMR (CDCl₃ + DMSO-*d*₆, 75 MHz) δ : 193.9, 158.6, 146.9, 136.2, 134.0, 128.9, 128.6, 128.0, 124.6, 121.0, 119.3, 116.6, 113.5, 112.4, 54.2, 26.7. HRMS (ESI, Orbitrap): calcd for C₁₈H₁₆N₃O₄ [M + H]⁺ 338.1141; found 338.1129.

1-(4-(3-Nitrophenyl)-3-(4-nitrophenyl)-1H-pyrazol-5-yl)ethanone, **3gae**. A total of 299 mg (85%) of **3gae** was obtained as a white solid, $R_f = 0.53$ (ethyl acetate/*n*-hexane, 1:1), mp 200–202 °C. IR (KBr, cm⁻¹): 3163, 2956, 1664, 1600, 1534, 1350, 1171, 1110. ¹H NMR (CDCl₃ + DMSO-d₆, 300 MHz) δ: 14.02 (bs, 1H), 8.28–8.10 (m, 4H), 7.64–7.55 (m, 2H), 7.52 (d, J = 8.5 Hz, 2H), 2.63 (bs, 3H). ¹³C NMR (CDCl₃ + DMSO-d₆, 75 MHz) δ: 193.1, 146.9, 146.0, 138.8, 135.7, 133.1, 128.3, 127.4, 124.3, 122.8, 121.3, 117.7, 26.7. HRMS (ESI, Orbitrap): calcd for C₁₇H₁₃N₄O₅ [M + H]⁺ 353.0886; found 353.0879.

4-(5-Acetyl-3-(3-methoxyphenyl)-1H-pyrazol-4-yl)benzonitrile, **3iad.** A total of 282 mg (89%) of **3iad** was obtained as a white solid, $R_f = 0.46$ (ethyl acetate/*n*-hexane, 1:1), mp 208–210 °C. IR (KBr, cm⁻¹): 3264, 3061, 3008, 2922, 2229, 1682, 1607, 1433, 1391, 1263. ¹H NMR (CDCl₃ + DMSO-d₆, 300 MHz) δ : 7.77 (d, J = 7.9 Hz, 2H), 7.40 (d, J = 7.9 Hz, 2H), 7.25 (t, J = 7.9 Hz, 1H), 6.92 (d, J = 8.1 Hz, 1H), 6.80–6.76 (m, 2H), 3.66 (s, 3H), 2.53 (bs, 3H). ¹³C NMR (CDCl₃ + DMSO-d₆, 75 MHz) δ : 191.9, 157.3, 145.8, 139.7, 136.3, 129.7, 129.5, 127.9, 127.3, 118.0, 116.9, 115.9, 112.4, 111.3, 107.7, 53.0, 25.4. HRMS (ESI, Orbitrap): calcd for C₁₉H₁₅N₃O₂Na [M + Na]⁺ 340.10415; found 340.10620.

4-(5-Acetyl-3-(3-chloro-4-nitrophenyl)-1H-pyrazol-4-yl)benzonitrile, **3iaf**. A total of 330 mg (90%) of **3iaf** was obtained as a white solid, $R_f = 0.59$ (ethyl acetate/n-hexane, 1:1), mp 259–260 °C. IR (KBr, cm⁻¹): 3447, 3268, 2235, 1670, 1531, 1364, 1294. ¹H NMR (CDCl₃ + DMSO- d_{6} , 300 MHz) δ : 7.98 (s, 1H), 7.87–7.58 (bs, 2H), 7.52–7.26 (m, 4H), 2.59 (bs, 3H). ¹³C NMR (CDCl₃, 125 MHz) δ : 192.2, 146.1, 137.1, 135.7, 130.5, 129.8, 127.0, 124.4, 122.8, 117.5, 117.0, 109.2, 25.8. HRMS (ESI, Orbitrap): calcd for C₁₈H₁₂ClN₄O₃ [M + H]⁺ 367.0598; found 367.0597.

4-(5-Acetyl-3-(4-nitrophenyl)-1H-pyrazol-4-yl)benzonitrile, **3iae**. A total of 292 mg (88%) of **3iae** was obtained as a white solid, $R_f = 0.40$ (ethyl acetate/*n*-hexane, 1:1), mp 250–252 °C. IR (KBr, cm⁻¹): 3245, 2232, 1687, 1599, 1512, 1441, 1337, 1246. ¹H NMR (CDCl₃ + DMSO- d_6 , 300 MHz) δ : 8.16 (d, J = 8.3 Hz, 2H), 7.68 (d, J = 6.5 Hz, 2H), 7.49 (d, J = 8.5 Hz, 2H), 7.42 (d, J = 7.4 Hz, 2H), 2.60 (bs, 3H). ¹³C NMR (CDCl₃ + DMSO- d_6 , 75 MHz) δ : 183.3, 146.2, 138.9, 136.7, 133.8, 131.0, 130.5, 127.6, 122.9, 117.7, 110.2, 26.7. HRMS (ESI, Orbitrap): calcd for C₁₈H₁₃N₄O₃ [M + H]⁺ 333.09877; found 333.09681.

1-(3-(4-Nitrophenyl)-4-*p*-tolyl-1H-pyrazol-5-yl)ethanone, **3kae**. A total of 273 mg (85%) of **3kae** was obtained as a yellow solid, $R_f = 0.42$ (ethyl acetate/*n*-hexane, 1:1), mp 210–212 °C. IR (KBr, cm⁻¹): 3449, 3262, 2925, 1667, 1597, 1507, 1338, 1203. ¹H NMR (CDCl₃ + DMSO- d_6 , 300 MHz) δ: 8.08 (d, J = 7.7 Hz, 2H), 7.73–7.48 (m, 2H), 7.40–7.07 (m, 4H), 2.42 (s, 3H), 2.13 (bs, 3H). ¹³C NMR (CDCl₃ + DMSO- d_6 , 75 MHz) δ: 189.9, 146.1, 137.2, 129.5, 128.9, 128.6, 127.4, 122.9, 122.0, 27.8, 20.7. HRMS (ESI, Orbitrap): calcd for C₁₈H₁₆N₃O₃ [M + H]⁺ 322.1192; found 322.1196.

1-(5-(3-Nitrophenyl)-4-propyl-1H-pyrazol-3-yl)ethanone, **3qag**. A total of 191 mg (70%) of **3qag** was obtained as a white solid, $R_f = 0.35$ (ethyl acetate/*n*-hexane, 3:7), mp 155–156 °C. IR (KBr, cm⁻¹): 3447, 3189, 1652, 1528, 1346. ¹H NMR (CDCl₃ + DMSO-*d*₆, 300 MHz) δ: 13.42 (bs, 1H), 8.43 (s, 1H), 8.24 (d, *J* = 7.5 Hz, 1H), 7.95–7.85 (m, 1H), 7.68 (t, *J* = 7.4 Hz, 1H), 2.83 (t, *J* = 7.0 Hz, 2H), 2.61 (s, 3H), 1.63–1.55 (m, 2H) 0.94 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (CDCl₃ + DMSO-*d*₆, 75 MHz) δ: 194.8, 147.2, 132.5, 128.9, 128.7, 127.2, 121.5,

121.2, 120.3, 26.5, 24.4, 22.7, 13.0. HRMS (ESI, Orbitrap): calcd for $C_{14}H_{16}N_3O_3$ [M + H]⁺ 274.1192; found 274.1195.

1-(5-(9-Ethyl-9H-carbazol-2-yl)-4-(3-nitrophenyl)-1H-pyrazol-3-yl)ethanone, **3gaj**. A total of 331 mg (78%) of **3gaj** was obtained as a yellow solid, $R_{\rm f} = 0.30$ (ethyl acetate/*n*-hexane, 3:7), mp 160–161 °C. IR (KBr, cm⁻¹): 3257, 2925, 1672, 1530, 1470, 1347, 1231. ¹H NMR (DMSO- d_{6} 300 MHz) δ : 13.09 (bs, 1H), 8.26 (d, J = 7.5 Hz, 1H), 8.15 (t, J = 7.5 Hz, 1H), 8.08 (d, J = 8.1 Hz, 1H), 7.96 (t, J = 8.1 Hz, 1H), 7.64 (t, J = 7.6 Hz, 1H), 7.54–7.40 (m, 3H), 7.33–7.22 (m, 3H), 4.39–7.32 (m, 2H), 2.65 (s, 3H), 1.45–1.40 (m, 3H). ¹³C NMR (DMSO- d_{6} , 75 MHz) δ : 194.1, 147.3, 143.3, 139.8, 139.3, 137.2, 134.8, 131.3, 129.1, 128.3, 127.9, 126.2, 125.7, 125.2, 122.1, 121.6, 120.1, 119.1, 118.3, 116.3, 109.3, 36.9, 27.2, 13.6. HRMS (ESI, Orbitrap): calcd for C₂₅H₂₁N₄O₃ [M + H]⁺ 425.1614; found 425.1619.

Typical Experimental Procedure for Alkylation of NH-Pyrazoles. In a 50 mL round-bottom flask, NH-pyrazole (1 mmol), ethyl α -bromoacetate (1.1 mmol), K₂CO₃ (3.0 mmol), and dry acetonitrile (20 mL) were mixed, and the reaction mixture was heated at 80 °C for 3 h. Next, the reaction mixture was evaporated to dryness, and the residue was extracted with ethyl acetate/water. The organic layer was dried over anhydrous sodium sulfate and concentrated to yield a crude reaction product, which was purified by silica-gel column chromatography using ethyl acetate/hexane in increasing polarity to yield the desired products (9kaaa–9gaea).

Ethyl 3-Acetyl-1-(2-ethoxy-2-oxoethyl)-4-p-tolyl-1H-pyrazole-5carboxylate, **9kaaa**. A total of 290 mg (81%) of **9kaaa** was obtained as a white solid, $R_f = 0.48$ (ethyl acetate/*n*-hexane, 3:7), mp 110–111 °C. IR (KBr, cm⁻¹): 2993, 1749, 1703, 1465, 1229. ¹H NMR (CDCl₃, 300 MHz) δ : 7.16 (s, 4H), 5.36 (s, 2H), 4.28 (q, J = 7.2 Hz, 2H), 4.10 (q, J = 7.2 Hz, 2H), 2.47 (s, 3H), 2.39 (s, 3H), 1.31 (t, J = 7.2 Hz, 3H), 0.98 (t, J = 7.2 Hz, 3H). ¹³C NMR (CDCl₃, 75 MHz) δ : 193.3, 167.4, 159.8, 147.1, 137.3, 132.1, 129.8, 128.5, 128.4, 128.1, 61.9, 61.3, 54.8, 28.1, 21.4, 14.1, 13.4. HRMS (ESI, Orbitrap): calcd for C₁₉H₂₃N₂O₅ [M + H]⁺ 359.1607; found 359.1600.

Ethyl 2-(3-Acetyl-5-(3-methoxyphenyl)-4-(3-nitrophenyl)-1H-pyrazol-1-yl)acetate, **9gada**. A total of 351 mg (83%) of **9gada** was obtained as a pale solid, $R_f = 0.56$ (ethyl acetate/*n*-hexane, 3:7), IR (KBr, cm⁻¹): 2935, 1750, 1689, 1528, 1350. ¹H NMR (CDCl₃, 500 MHz) δ : 8.08–8.05 (m, 2H), 7.55 (d, J = 7.2 Hz, 1H), 7.38 (t, J = 7.6Hz, 1H), 7.29 (t, J = 7.7 Hz, 1H), 6.93 (d, J = 7.6 Hz, 1H), 6.77 (d, J =7.2 Hz, 1H), 6.72 (s, 1H), 4.88 (s, 2H), 4.25 (q, J = 6.9 Hz, 2H), 3.72 (s, 3H), 2.63 (s, 3H), 1.27 (t, J = 6.9 Hz, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ : 194.2, 167.3, 159.7, 147.6, 147.1, 144.4, 136.6, 133.6, 130.2, 128.9, 128.4, 125.4, 122.3, 121.9, 120.2, 115.5, 115.3, 62.1, 52.2, 51.7, 27.8, 14.1. HRMS (ESI, Orbitrap): calcd for C₂₂H₂₂N₃O₆ [M + H]⁺ 424.1509; found 424.1501.

Ethyl 2-(3-Acetyl-4-(3-nitrophenyl)-5-(4-nitrophenyl)-1H-pyrazol-1-yl)acetate, **9gaea**. A total of 372 mg (85%) of **9gaea** was obtained as a white solid, $R_f = 0.52$ (ethyl acetate/*n*-hexane, 3:7), mp 170–171 °C. IR (KBr, cm⁻¹): 3097, 2924, 2850, 1748, 1687, 1524, 1346. ¹H NMR (CDCl₃, 500 MHz) δ : 8.25 (d, J = 8.7 Hz, 2H), 8.11 (d, J = 8.1Hz, 1H), 8.04 (s, 1H), 7.50 (d, J = 7.8 Hz, 1H), 7.45–7.40 (m, 3H), 4.89 (s, 2H), 4.26 (q, J = 7.1 Hz, 2H), 2.63 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H). ¹³C NMR (CDCl₃, 75 MHz) δ : 193.8, 166.9, 148.4, 147.8, 147.3, 142.2, 136.4, 134.3, 132.8, 131.2, 128.8, 125.3, 124.2, 122.4, 121.1, 62.5, 51.9, 27.5, 14.0. HRMS (ESI, Orbitrap): calcd for C₂₁H₁₉N₄O₇ [M + H]⁺ 439.1254; found 439.1268.

Synthesis of the Dihydropyrazole 7naa. In a 25 mL roundbottom flask, furfural-acetyl acetone adduct 1na (1 mmol), EDA (1.01 mmol), 4 Å molecular sieves (500 mg), and anhydrous toluene (10 mL) were mixed under nitrogen atmosphere. The reaction mixture was heated at 70 °C for 24 h. Next, molecular sieves were filtered off, and the filtrate was concentrated to yield a crude reaction product, which was purified by silica-gel column chromatography to yield pure compound 7naa.

Ethyl 5,5-Diacetyl-4-(furan-2-yl)-4,5-dihydro-1H-pyrazole-3-carboxylate, **7naa**. A total of 380 mg (96%) of **7naa** was obtained as a white solid, $R_f = 0.48$ (ethyl acetate/*n*-hexane, 3:7), mp 104–105 °C. ¹H NMR (CDCl₃, 500 MHz) δ : 7.44 (bs, 1H), 7.33 (m, 1H), 6.34 (m, 1H), 6.26 (m, 1H), 5.37 (s, 1H), 4.26–4.15 (m, 2H), 2.27 (s, 3H), 1.72 (s, 3H), 1.24–1.20 (m, 3H). ^{13}C NMR (CDCl₃, 125 MHz) δ : 201.5, 200.7, 160.5, 147.6, 142.7, 142.5, 111.3, 109.8, 90.2, 61.3, 48.4, 26.1, 25.7, 13.9. HRMS (ESI, Orbitrap): calcd for $C_{14}H_{17}N_2O_5$ [M + H]⁺ 293.11375; found 293.11338.

 $1\mathcal{-}(3\mathcal{-}Nitrophenyl)\mathcal{-}4\mathcal{-}phenyl\mathcal{-}1\mathcal{H}-pyrazol\mathcal{-}5\mathcal{-}yl)\mathcal{E}ethanone, 3teg. A total of 230 mg (75%) of 3teg was obtained as a white solid, <math display="inline">R_{\rm f}$ = 0.40 (ethyl acetate/n-hexane, 3:7), mp 190–191 °C. IR (KBr, cm $^{-1}$): 3255, 2925, 1662, 1527, 1341. $^{1}{\rm H}$ NMR (CDCl₃, 500 MHz) δ : 11.50 (bs, 1H), 8.29 (s, 1H), 8.10 (d, J = 8.2 Hz, 1H), 7.73 (d, J = 7.8 Hz, 1H), 7.52–7.47 (m, 3H), 7.40 (t, J = 8.1 Hz, 1H), 7.37–7.30 (m, 2H), 2.13 (s, 3H). $^{13}{\rm C}$ NMR (CDCl₃, 75 MHz) δ : 147.5, 132.7, 131.7, 130.0, 129.7, 128.7, 128.1, 127.8, 127.5, 121.6, 27.7. HRMS (ESI, Orbitrap): calcd for $C_{17}H_{14}N_3O_3$ [M + H]⁺ 308.1035; found 308.1040.

Synthesis of (\hat{E}) -4-Phenylbut-3-en-2-one, 1te. Compound 1te was synthesized from benzaldehyde and acetone using literature protocol.²³

The compound **1te** was obtained as a white solid (0.82 g, 56%, 10 mmol scale reaction), mp 40–41 $^{\circ}$ C (lit 40–41 $^{\circ}$ C).²³ Spectroscopic data was found in accordance with literature.²⁴

ASSOCIATED CONTENT

S Supporting Information

Crystallographic data for compound **9gaea** and spectral data. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Authors

*E-mail: ramaurya@iict.res.in (R. A. Maurya).

*E-mail: ahmedkamal@iict.res.in (A. Kamal).

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

R.A.M. is thankful to Department of Science & Technology India for financial support (Grants GAP 0378 and GAP 0470). Financial support in part from 12th Five Year Plan Project "Affordable Cancer Therapeutics (ACT-CSC-0301)" is also acknowledged. K.N.V.S. and G.S.M. acknowledge NIPER India for their fellowships. P.R.A. acknowledges CSIR-New Delhi for his fellowship.

REFERENCES

(1) Kumar, V.; Kaur, K.; Gupta, G. K.; Sharma, A. K. Eur. J. Med. Chem. 2013, 69, 735.

(2) (a) Sridhar, R.; Perumal, P. T.; Etti, S.; Shanmugam, G.; Ponnuswamy, M. N.; Prabavathy, V. R.; Mathivanan, N. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 6035. (b) Liu, J.-J.; Sun, J.; Fang, Y.-B.; Yang, Y.-A.; Jiao, R.-H.; Zhu, H.-L. *Org. Biomol. Chem.* **2014**, *12*, 998.

(3) Ouyang, G.; Cai, X.-J.; Chen, Z.; Song, B.-A.; Bhadury, P. S.; Yang, S.; Jin, L.-H.; Xue, W.; Hu, D.-Y.; Zeng, S. J. Agric. Food Chem. 2008, 56, 10160.

(4) Abdel-Magid, A. F. ACS Med. Chem. Lett. 2014, 5, 730.

(5) Bebernitz, G. R.; Argentieri, G.; Battle, B.; Brennan, C.; Balkan, B.; Burkey, B. F.; Eckhardt, M.; Gao, J.; Kapa, P.; Strohschein, R. J.;

Schuster, H. F.; Wilson, M.; Xu, D. D. J. Med. Chem. 2001, 44, 2601.
(6) Chang, C.-P.; Wu, C.-H.; Song, J.-S.; Chou, M.-C.; Wong, Y.-C.;
Lin, Y.; Yeh, T.-K.; Sadani, A. A.; Ou, M.-H.; Chen, K.-H.; Chen, P.-H.; Kuo, P.-C.; Tseng, C.-T.; Chang, K.-H.; Tseng, S.-L.; Chao, Y.-S.;

Hung, M.-S.; Shia, K.-S. J. Med. Chem. 2013, 56, 9920. (7) Habeeb, A. G.; Rao, P. N. P.; Knaus, E. E. J. Med. Chem. 2001, 44,

3039.
(8) Stauffer, S. R.; Coletta, C. J.; Tedesco, R.; Nishiguchi, G.; Carlson, K.; Sun, J.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. J. Med. Chem. 2000, 43, 4934.

(9) Lan, R.; Liu, Q.; Fan, P.; Lin, S.; Fernando, S. R.; McCallion, D.; Pertwee, R.; Makriyannis, A. J. Med. Chem. **1999**, 42, 769.

(10) Kotsuki, H.; Wakao, M.; Hayakawa, H.; Shimanouchi, T.; Shiro, M. J. Org. Chem. **1996**, *61*, 8915.

(11) ElKholy, Y. M.; Abd El-Hafiz, S. A. Pigm. Resin Technol. 1994, 23, 3.

(12) (a) Yet, L. In Comprehensive Heterocyclic Chemistry III; Katritzky, A. R., Ramsden, C. A., Scriven, E. F. V., Taylor, R. J. K., Eds.; Elsevier: Oxford, 2008; Vol. 4, p 1. (b) Stanovnik, B.; Svete, J. Science of Synthesis Houben-Weyl Methods of Molecular Transformations; Thieme: Stuttgart, 2002; Vol. 12, Category 2, Chapter 12.1, p 15. (c) Stanovnik, B.; Svete, J. Chem. Rev. 2004, 104, 2433. (d) Gerstenberger, B. S.; Rauckhorst, M. R.; Starr, J. T. Org. Lett. 2009, 11, 2097. (e) Zhang, X.; Kang, J.; Niu, P.; Wu, J.; Yu, W.; Chang, J. J. Org. Chem. 2014, 79, 10170.

(13) (a) Attanasi, O. A.; de Crescentini, L.; Favi, G.; Mantellini, F.; Mantenuto, S.; Nicolini, S. J. Org. Chem. **2014**, 79, 8331. (b) Kong, Y.; Tang, M.; Wang, Y. Org. Lett. **2014**, 16, 576. (c) Zhang, F.-G.; Wei, Y.; Yi, Y.-P.; Nie, J.; Ma, J.-A. Org. Lett. **2014**, 16, 3122. (d) Wang, X.; Pan, Y.-m.; Huang, X.-c.; Mao, Z.-y.; Wang, H.-s. Org. Biomol. Chem. **2014**, 12, 2028. (e) Wu, L.-L.; He, Y.-C.; Ge, T.; Zhang, L.; Fu, X.-L.; Fu, H.-Y.; Chen, H.; Li, R.-X. Synthesis **2012**, 44, 1577. (f) Guo, H.; Zhang, D.; Zhu, C.; Li, J.; Xu, G.; Sun, J. Org. Lett. **2014**, 16, 3110.

(14) Zhang, G.; Ni, H.; Chen, W.; Shao, J.; Liu, H.; Chen, B.; Yu, Y. Org. Lett. 2013, 15, 5967.

(15) (a) Xie, J.-W.; Wang, Z.; Yang, W.-J.; Kong, L.-C.; Xu, D.-C. Org. Biomol. Chem. 2009, 7, 4352. (b) Tang, M.; Zhang, W.; Kong, Y. Org. Biomol. Chem. 2013, 11, 6250.

(16) (a) Muruganantham, R.; Mobin, S. M.; Namboothiri, I. N. N. Org. Lett. 2007, 9, 1125. (b) Muruganantham, R.; Namboothiri, I. J. Org. Chem. 2010, 75, 2197. (c) Kumar, R.; Namboothiri, I. N. N. Org. Lett. 2011, 13, 4016.

(17) Babinski, D. J.; Aguilar, H. R.; Still, R.; Frantz, D. E. J. Org. Chem. 2011, 76, 5915.

(18) Wang, L.; Huang, J.; Gong, X.; Wang, J. Chem.—Eur. J. 2013, 19, 7555.

(19) Kapure, J. S.; Reddy, C. N.; Adiyala, P. R.; Nayak, R.; Nayak, V. L.; Nanubolu, J. B.; Singarapu, K. K.; Maurya, R. A. *RSC Adv.* **2014**, *4*, 38425.

(20) Ji, F.; Peng, H.; Zhang, X.; Lu, W.; Liu, S.; Jiang, H.; Liu, B.; Yin, B. J. Org. Chem. **2015**, 80, 2092.

(21) Chenon, M. T.; Coupry, C.; Grant, D.; Pugmire, R. J. J. Org. Chem. 1977, 42, 659.

(22) Wulfman, D. S.; Yousefian, S.; White, J. M. Synth. Commun. 1988, 18, 2349.

(23) Gladkowski, W.; Skrobiszewski, A.; Mazur, M.; Siepka, M.; Pawlak, A.; Obminska-Mrukowicz, B.; Bialonska, A.; Poradowski, D.; Drynda, A.; Urbaniak, M. *Tetrahedron* **2013**, *69*, 10414.

(24) Aelvoet, K.; Batsanov, A. S.; Blatch, A. J.; Grosjean, C.; Patrick, L. G. F.; Smethurst, C. A.; Whiting, A. *Angew. Chem., Int. Ed.* **2008**, *47*, 768.